Aurion Biotech to present clinical data at ASCRS 2024

(Image Credit: AdobeStock/wellphoto)

Aurion Biotech announced several presentations scheduled during the American Society of Cataract and Refractive Surgery 2024 Annual Meeting, being held April 5 to 8 in Boston, Massachusetts.

According to a news release, during Eyecelerator and ASCRS 2024, data will be presented from the company’s Escalón and IOTA studies, which treated subjects with its combination cell therapy product (biologic/drug) comprised of neltependocel (allogeneic human corneal endothelial cells [CECs]) and Y-27632 (an inhibitor of Rho-associated, coiled-coil containing protein kinase [ROCK]).¹

“We are delighted to share additional insights into these clinical studies, in multiple sessions at the Eyecelerator and ASCRS 2024 meetings,” Michael Goldstein, MD, president and chief medical officer, Aurion Biotech, said in the news release. “We believe these presentations will be of significant interest to the ophthalmology community, as they highlight the exciting potential of our cell therapy to treat patients with corneal endothelial disease.”

The company noted the schedule of presentations includes:

• During Eycelerator, Greg Kunst, CEO of Aurion Biotech, will present Corneal Endothelial Cell Therapy for Corneal Endothelial Disease at 1 pm Thursday, April 4, at the Omni Boston Hotel at the Seaport, Level 2 Marquis room.
• Michael Goldstein, MD, president and chief medical officer, Aurion, and Nysha Blender, OD, senior director medical affairs, will present Human Corneal Endothelial Cell Transplantation Combined with Cataract Extraction and PCIOL in Subject with Corneal Edema at 2 pm Sunday, April 7 at the Boston Convention & Exhibition Center (BCEC) - Level 2.
• Elizabeth Yeu, MD, president, ASCRS; Virginia Eye Consultants, will present at 8:45 am Monday, April 8, at the Boston Convention & Exhibition Center (BCEC) - Meeting Level 2, Room 259A.

According to the news release, the company recently opened a Phase 1 / 2 clinical trial (ABA-1 / CLARA), a prospective, multi-center, randomized, double-masked, parallel-arm cell dose-ranging study in subjects with corneal edema secondary to corneal endothelial dysfunction. The study will evaluate three different doses of neltependocelused in combination with Y-27632. Approximately 100 subjects will be randomized in sites in the U.S. and in Canada.

The ABA-1 / CLARA trial is designed to assess the safety, tolerability, and efficacy of AURN001 for the treatment of corneal edema secondary to corneal endothelial dysfunction. The primary endpoint is the percentage of subjects who gain 3 lines of vision at 6 months.¹

The company noted in the news release its combination cell therapy recently received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), for the treatment of bullous keratopathy, marking the first-ever regulatory approval in the world for an allogeneic cell therapy to treat corneal endothelial disease.¹

Reference:

1. Aurion Biotech to Present Clinical Data at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. www.businesswire.com. Published April 2, 2024. Accessed April 2, 2024. https://www.businesswire.com/news/home/20240402254715/en/Aurion-Biotech-to-Present-Clinical-Data-at-the-2024-American-Society-of-Cataract-and-Refractive-Surgery-ASCRS-Annual-Meeting